Clovis Oncology Accounts Payable

Clovis Oncology (CLVS) currently reports a accounts payable of $18M as of September 2022. That compares with $24M in the prior-year period — down 23.9% year over year. Use the charts on this page to explore Clovis Oncology's accounts payable history and peer comparisons.

Clovis Oncology's accounts payable decreased from $24M to $18M — a 23.9% year-over-year decrease (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Clovis Oncology reported $18M in accounts payable as of September 2022. That compares with $24M in the prior-year period — down 23.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $18M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Clovis Oncology, and consider following CLVS for alerts when major investors trade the stock.

Clovis Oncology is classified in the Healthcare sector. On accounts payable, it currently shows $18M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CLVS with unrelated industries.